vimarsana.com
Home
Live Updates
Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2) : vimarsana.com
Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2)
Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2) Covicept has initiated a Phase 2 multi-center
Related Keywords
Germany ,
United States ,
Netherlands ,
Singapore ,
Brazil ,
California ,
San Diego ,
Switzerland ,
Laura Asbjornsen ,
Van Deventer ,
Jeffrey Eskowith ,
Sam Tsimikas ,
Sue Charles ,
Sander Van Deventer ,
Brunom Tomazini ,
Ashley Tapp ,
Philip Gordts ,
Kostenloser Wertpapierhandel ,
Head Of Communications ,
Healthtech Investment Forum In Basel ,
Covicept Therapeutics Inc ,
Consilium Strategic Communications ,
Covicept Therapeutics ,
Chief Executive Officer ,
Covicept Board ,
Operating Partner ,
Annual Healthtech Investment Forum ,
Spotlight Showcase ,
California United States ,
Professor Sam Tsimikas ,
Professor Philip Gordts ,
Professor Jeffrey ,
Chief Executive ,
Forbion Operating ,
Covicept ,
Herapeutics ,
Nitiates ,
Hase ,
Linical ,
Study ,
Mural ,
Mall ,
Olecule ,
Treatment ,
Patients ,
Covid ,
Cars ,
vimarsana.com © 2020. All Rights Reserved.